Regensburg, Germany, October 24, 2011 / B3C newswire / - Lophius Biosciences, a leading developer of novel T-cell based diagnostic testing systems, today announces the conclusion of the product development of its T-Track© CMV/EBV tests, which were developed on the basis of its proprietary UREA technology. Both tests are designed to determine the functionality of the cell-mediated immune response (CMI) in immunodeficient patients who are either Cytomegalovirus (CMV) or Epstein-Barr virus (EBV) seropositive. In the ideal case the T-Track tests should allow an HLA-independent semi-quantitative determination of the immune status of patients who are undergoing dialysis or who have had a transplant. A clinical validation study with > 120 patients will be carried out over the next few weeks with leading clinical partners in the field of dialysis. Following successful completion, Lophius Biosciences aims to market the T-Track© CMV/EBV tests as CE-certified products from the beginning of 2012.
“The conclusion of the development of the tests and the start of the clinical validation study for the T-Track© CMV/EBV tests represent significant milestones in our company’s history. We are delighted with the strong interest shown in our diagnostic products during the annual meeting of the German Transplantation Society in Regensburg at the beginning of October 2011,” said Dr. Michael Lutz, CEO of Lophius Biosciences.
About Lophius Biosciences
Lophius Biosciences GmbH develops and markets innovative T-cell based testing systems for diagnostics and possible therapy control in the fields of transplantation, infection and autoimmune diseases.
Contact:
Lophius Biosciences GmbH
Josef-Engert-Str. 13
D-93053 Regensburg/Germany
Tel: +49 941 6309 1972
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
www.lophius.de